Acorda announces royalty monetization transactions for $53 million
Acorda Therapeutics announced a $40 million royalty monetization with HealthCare Royalty Partners and a $13 million royalty monetization with H. Lundbeck. In return, HCR obtains the right to receive royalty revenue on FAMPYRAź payable by Biogen, up to an agreed upon threshold of royalties. November 17, 2017